Mihály Cserepes

506 total citations
21 papers, 380 citations indexed

About

Mihály Cserepes is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mihály Cserepes has authored 21 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mihály Cserepes's work include Lung Cancer Treatments and Mutations (6 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Melanoma and MAPK Pathways (4 papers). Mihály Cserepes is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Melanoma and MAPK Pathways (4 papers). Mihály Cserepes collaborates with scholars based in Hungary, Austria and Germany. Mihály Cserepes's co-authors include József Tóvári, Balázs Hegedűs, József Tı́már, Gergely Szakács, Szilárd Tóth, Michael Grusch, Pál Szabó, Judit Moldvay, Zoltán Lohinai and Tamás Barbai and has published in prestigious journals such as Nucleic Acids Research, Cell Metabolism and Cancer Research.

In The Last Decade

Mihály Cserepes

19 papers receiving 377 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mihály Cserepes Hungary 11 201 178 137 64 25 21 380
Nikko Brix Germany 8 244 1.2× 155 0.9× 109 0.8× 58 0.9× 8 0.3× 13 503
Hisayuki Kobayashi Japan 14 301 1.5× 106 0.6× 168 1.2× 81 1.3× 13 0.5× 20 484
Marloes Zoetemelk Switzerland 7 110 0.5× 107 0.6× 40 0.3× 50 0.8× 17 0.7× 9 258
Steve Wagner Germany 6 190 0.9× 160 0.9× 58 0.4× 77 1.2× 6 0.2× 8 341
Sandra Ictech United States 9 102 0.5× 184 1.0× 180 1.3× 70 1.1× 6 0.2× 12 469
James Zweibel United States 8 123 0.6× 258 1.4× 39 0.3× 70 1.1× 7 0.3× 10 370
Ranjana Kanchan United States 12 170 0.8× 242 1.4× 52 0.4× 135 2.1× 5 0.2× 20 518
Mohammad Sayeeduddin United States 10 149 0.7× 160 0.9× 159 1.2× 83 1.3× 8 0.3× 12 421
Francesca Bizzaro Italy 9 109 0.5× 145 0.8× 26 0.2× 92 1.4× 7 0.3× 13 286

Countries citing papers authored by Mihály Cserepes

Since Specialization
Citations

This map shows the geographic impact of Mihály Cserepes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mihály Cserepes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mihály Cserepes more than expected).

Fields of papers citing papers by Mihály Cserepes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mihály Cserepes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mihály Cserepes. The network helps show where Mihály Cserepes may publish in the future.

Co-authorship network of co-authors of Mihály Cserepes

This figure shows the co-authorship network connecting the top 25 collaborators of Mihály Cserepes. A scholar is included among the top collaborators of Mihály Cserepes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mihály Cserepes. Mihály Cserepes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Erdélyi, Katalin, Tamás Ditrói, Ágnes Czikora, et al.. (2025). Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma. Cell Metabolism. 37(5). 1171–1188.e9. 4 indexed citations
2.
Molnár, Eszter, Luca Hegedüs, Ivan Ranđelović, et al.. (2024). Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors. British Journal of Cancer. 130(6). 1059–1072. 15 indexed citations
3.
Cserepes, Mihály, et al.. (2024). Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma. Scientific Reports. 14(1). 20482–20482.
4.
Ranđelović, Ivan, et al.. (2024). Targeting hypoxia in combination with paclitaxel to enhance therapeutic efficacy in breast and ovarian cancer. Biomedicine & Pharmacotherapy. 180. 117601–117601. 1 indexed citations
5.
Cserepes, Mihály, et al.. (2024). [Immunomodulation in the tumor microenvironment: Therapeutic potential of combined inhibition of tumor hypoxia and PD-1/ PD-L1].. PubMed. 68(2). 126–135.
6.
Butz, Henriett, Viktória Vereczki, István Likó, et al.. (2023). Context-Dependent Role of Glucocorticoid Receptor Alpha and Beta in Breast Cancer Cell Behaviour. Cells. 12(5). 784–784. 3 indexed citations
7.
Tóvári, József, et al.. (2023). Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential Targets. Cells. 12(14). 1919–1919. 7 indexed citations
8.
Schmidhuber, Sabine, Sandra Scheiblhofer, Richard Weiss, et al.. (2022). A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in Mice. Vaccines. 10(9). 1432–1432. 8 indexed citations
9.
Cserepes, Mihály, Dóra Türk, Erzsébet Rásó, et al.. (2022). EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer. Cancers. 14(10). 2407–2407. 4 indexed citations
10.
Cserepes, Mihály, Balázs Szabó, Dóra Türk, et al.. (2021). EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas. Pathology & Oncology Research. 27. 620256–620256. 3 indexed citations
11.
12.
Naffa, Randa, Luca Hegedüs, Katalin Pászty, et al.. (2020). P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b. Cells. 9(5). 1209–1209. 20 indexed citations
13.
Cserepes, Mihály, Dóra Türk, Szilárd Tóth, et al.. (2019). Unshielding Multidrug Resistant Cancer through Selective Iron Depletion of P-Glycoprotein–Expressing Cells. Cancer Research. 80(4). 663–674. 29 indexed citations
14.
Baska, Ferenc, Zoltán Nemes, Judit Dobos, et al.. (2019). Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases. European Journal of Medicinal Chemistry. 184. 111710–111710. 12 indexed citations
15.
Paku, Sándor, István Kenessey, Tamás Garay, et al.. (2017). Cell type-dependent HIF1 α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells. Oncotarget. 8(27). 44498–44510. 25 indexed citations
16.
Füredi, András, Kornélia Szebényi, Szilárd Tóth, et al.. (2017). Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. Journal of Controlled Release. 261. 287–296. 78 indexed citations
17.
Kenessey, István, Mihály Cserepes, Dávid Molnár, et al.. (2016). KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. Oncotarget. 7(48). 79503–79514. 12 indexed citations
18.
Lohinai, Zoltán, Mir Alireza Hoda, Katalin Fábián, et al.. (2015). Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. Journal of Thoracic Oncology. 10(5). 738–746. 62 indexed citations
19.
Kenessey, István, Mihály Cserepes, Judit Dobos, et al.. (2015). Abstract 47: KRAS-mutation dependent effect of zoledronic acid in human NSCLC preclinical models. Cancer Research. 75(15_Supplement). 47–47. 1 indexed citations
20.
Cserepes, Mihály, Gyula Ostoros, Zoltán Lohinai, et al.. (2014). Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. European Journal of Cancer. 50(10). 1819–1828. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nikko Brix Breakdown of academic impact, for papers by Hisayuki Kobayashi Breakdown of academic impact, for papers by Marloes Zoetemelk Breakdown of academic impact, for papers by Steve Wagner Breakdown of academic impact, for papers by Sandra Ictech Breakdown of academic impact, for papers by James Zweibel Breakdown of academic impact, for papers by Ranjana Kanchan Breakdown of academic impact, for papers by Mohammad Sayeeduddin Breakdown of academic impact, for papers by Francesca Bizzaro
Rankless by CCL
2026